
    
      This study will be a open-label, single center, pharmacokinetic, and safety study of KX2-391
      Ointment administered topically to the face or balding scalp of subjects with actinic
      keratosis.

      The study consists of Screening, Treatment, and Follow-up Periods. Eligible subjects will
      receive 5 consecutive days of topical treatment, to be applied at the same location. Activity
      (lesion counts) and safety evaluations will be performed.
    
  